PATENT Attorney Docket No.: PP019817.0003

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First class mail with sufficient postage in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the below-identified date.

Arrendle Brown Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

XU, Feng

Conf. No.: 4572

Serial No.:

10/567,940

Group Art Unit: 1632

Filed: September 27, 2006

Examiner: M.C. Wilson

For:

INACTIVATED HOST CELL DELIVERY OF POLYNUCLEOTIDES ENCODING

IMMUNOGENS

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on Form PTO/SB/08, submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

This Information Disclosure Statement is being filed:

within three months of th	ne filing date	of the patent	application.
within thee months of a	io minib auto	or the paten.	appinouncin

Attorney Docket No.: PP019817.0003

		n three months of the date of entry into the national stage as set forth in 37 R. § 1.491 of the international application.			
\boxtimes	befo	before the mailing date of a first Office Action on the merits.			
	after	after the mailing date of a first Office Action on the merits, but before the mailing			
	date	date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance			
	unde	under 37 C.F.R. § 1.311, and accordingly is accompanied by:			
		the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);			
		or			
		the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or			
		No fee is owed by the applicant(s).			
	In ac	cordance with 37 C.F.R. § 1.129(a), this Information Disclosure Statement is			
	being	being filed in connection with the first or second After Final Submission,			
	and a	and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e) (see			
	"Stat	"Statement" below) and the fee of \$180.00 as set forth in 37 C.F.R. § 1.17(p), is			
	attacl	ned.			
	after	the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a			
	Notic	te of Allowance under 37 C.F.R. § 1.311, but before the payment of the Issue			
	Fee,	Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e),			
	(see '	(see "Statement," and "Fees" below).			
\boxtimes	Copi	es of each of the non-U.S. Patent documents listed on the attached Form			
	PTO	/SB/08, are enclosed herewith.			
	EXC	EPT THAT:			
		In view of the voluminous nature of reference @@, and the likelihood that			
		this reference is available to the Examiner, copies are not enclosed			
		herewith.			

Attorney Docket No.: PP019817.0003

		In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached Form PTO/SB/08 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.		
		If any of the foregoing publications are not available to the Examiner Applicant will endeavor to supply copies at the Examiner's request.		
Concis	se Expl	anation Requirement		
	The "concise explanation" requirement (non-English references) for references under 37 C.F.R. § 1.98(a)(3) is satisfied by:			
		the explanation provided on the attached sheet.		
		the explanation provided in the Specification.		
		submission of the enclosed International Search Report.		
		submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action		
		the English-language abstract provided on the cover page of B2.		
Staten	nent un	der 37 C.F.R. § 1.97(e)		
	The undersigned attorney hereby states that each item contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.			
Fees				
\boxtimes	No Fee	e is owed by the applicant(s).		

	The Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p)						
	is enclosed herewith.						
Meth	Method of Payment of Fees						
	Attached is a check in the amount of \$ This form is submitted						
	in duplicate.						
	Charge Deposit Account No. 03-1664 in the amount of \$180.00. This form is						
	submitted in duplicate.						
\boxtimes	Please charge any deficiency or credit any overpayment to Deposit Account 03-						
	1664.						
	No fee or Statement is required under 37 C.F.R. § 1.97(b).						
	Respectfully submitted,						
	777						
	Helen Lee						
	Registration No. 39,270						

Dated: March 19, 2008

NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Intellectual Property Dept. - R338

4560 Horton Street

Emeryville, CA 94608-2916

Telephone: (510) 923-2192

Facsimile: (510) 655-3542